Skip to main content

Contra Pfizer

Buy Article:

$24.00 plus tax (Refund Policy)

Against a background of longstanding concerns that antidepressants may trigger suicidality, the Food and Drug Administration (FDA) in 2004 convened two committees to review the issues. Prior to the second meeting Pfizer posted an extensive ad hominem attack on me on FDA's website. There was no opportunity to post a response. This article covers the points made in response and sheds some light on pharmaceutical company handling of debates about adverse events.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Data/Media
No Metrics

Keywords: FDA; SERTRALINE; SUICIDE; WARNINGS

Document Type: Research Article

Publication date: 2005-09-01

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more